A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Public ClinicalTrials.gov record NCT02677896. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study also evaluated the safety of enzalutamide plus ADT in mHSPC.
Study identification
- NCT ID
- NCT02677896
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2016 (Actual)
- Primary completion
- Oct 14, 2018 (Actual)
- Completion
- Jul 31, 2024 (Actual)
- Last update posted
- Oct 24, 2025
2016 – 2024
United States locations
- U.S. sites
- 34
- U.S. states
- 23
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US10016 | Homewood | Alabama | 35209 | — |
| Site US10007 | Anchorage | Alaska | 99503 | — |
| Site US10008 | Tucson | Arizona | 85741 | — |
| Site US10034 | Fountain Valley | California | 92708 | — |
| Site US10056 | La Jolla | California | 92093 | — |
| Site US10026 | Santa Rosa | California | 95403 | — |
| Site US10035 | Aurora | Colorado | 80045 | — |
| Site US10050 | Denver | Colorado | 80220 | — |
| Site US10048 | St. Petersburg | Florida | 33710 | — |
| Site US10054 | Thomasville | Georgia | 31792 | — |
| Site US10015 | Chicago | Illinois | 60637 | — |
| Site US10043 | Springfield | Illinois | 62703 | — |
| Site US10045 | Jeffersonville | Indiana | 47130 | — |
| Site US10020 | West Des Moines | Iowa | 50266 | — |
| Site US10055 | Kansas City | Kansas | 66160-7233 | — |
| Site US10017 | Towson | Maryland | 21204 | — |
| Site US10036 | Omaha | Nebraska | 68114 | — |
| Site US10018 | Lawrenceville | New Jersey | 08648 | — |
| Site US10025 | Newburgh | New York | 12550 | — |
| Site US10029 | Syracuse | New York | 13210 | — |
| Site US10068 | Charlotte | North Carolina | 28207 | — |
| Site US10009 | Concord | North Carolina | 28025 | — |
| Site US10014 | Durham | North Carolina | 27710 | — |
| Site US10060 | Greenville | North Carolina | 27834 | — |
| Site US10044 | Middleburg Heights | Ohio | 44130 | — |
| Site US10011 | Lancaster | Pennsylvania | 17604 | — |
| Site US10012 | Myrtle Beach | South Carolina | 29572 | — |
| Site US10059 | Nashville | Tennessee | 37208 | — |
| Site US10046 | Dallas | Texas | 75231 | — |
| Site US10004 | Dallas | Texas | 75390-9110 | — |
| Site US10040 | Virginia Beach | Virginia | 23462 | — |
| Site US10002 | Burien | Washington | 98166 | — |
| Site US10013 | Seattle | Washington | 98101 | — |
| Site US10028 | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 169 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02677896, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02677896 live on ClinicalTrials.gov.